BLA 205692 · Eli Lilly and CO
Basaglar
Insulin Glargine · Subcutaneous · Insulin Analog
Last checked: Nov 20, 2026Latest source record: Jul 20, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Dec 16, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
679
239 Phase 3, 12 recruiting
FAERS reports
45,246
26,158 serious, 3,004 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 16, 2026.
BASAGLAR ® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. BASAGLAR ® is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use : Not recommended for treating diabetic ketoacidosis. ( 1 ) Limitations of Use BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.
Mechanism: The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analog lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BASAGLAR · INSULIN GLARGINE 300 UNITS/3ML (100 UNITS/ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Glargine" as an intervention, any sponsor and status, largest first.
- The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00069784 · 12,537 participants · Start Aug 2003 · Primary completion Dec 2011
Drug: insulin glargine (HOE901); omega-3 polyunsaturated fatty acids (PUFA) and 1 more · For: Diabetes Mellitus, Non-Insulin-Dependent
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Cove, Australia · 40 sites in all
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 DiabetesPivotal-lookingCompleted
GRADE Study GroupAcademic, hospital or other
NCT01794143 · 7,850 participants · Start May 2013 · Primary completion Apr 30, 2021
Drug: Sulfonylurea (glimepiride); DPP-4 inhibitor (sitagliptin) and 2 more · For: Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications
Sites: Birmingham, Alabama; Phoenix, Arizona; San Diego, California · 36 sites in all
- A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular EventsPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01959529 · 7,637 participants · Start Oct 29, 2013 · Primary completion Oct 16, 2016
Drug: insulin degludec; insulin glargine · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Montgomery, Alabama; Gilbert, Arizona · 446 sites in all
- A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes MellitusPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00399724 · 7,376 participants · Start Mar 2002 · Primary completion Aug 2003
Drug: Insulin glargine · For: Diabetes Mellitus, Type 2
- Glycemic Optimization Treatment StudyPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00552370 · 5,062 participants · Start Mar 2003 · Primary completion Mar 2005
Drug: Lantus® · For: Diabetes Mellitus, Type 2
- An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical PracticePivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00576368 · 4,464 participants · Start Jun 2003
Drug: INSULIN GLARGINE · For: Diabetes Mellitus
Sites: Brussels, Belgium
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT02451137 · 3,304 participants · Start Jun 16, 2015 · Primary completion Mar 2, 2018
Drug: Insulin glargine, 300 U/ml; Insulin glargine, 100 U/ml and 2 more · For: Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Gulf Shores, Alabama; Guntersville, Alabama · 427 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased7,220
- incorrect dose administered2,585
- drug ineffective2,134
- visual impairment2,008
- hypoglycaemia1,944
- blood glucose decreased1,684
- nausea1,591
- accidental underdose1,544
- diarrhoea1,438
- injection site pain1,423
- fatigue1,345
- inappropriate schedule of product administration1,306
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 99 |
| 2005 | 108 |
| 2006 | 89 |
| 2007 | 111 |
| 2008 | 169 |
| 2009 | 191 |
| 2010 | 299 |
| 2011 | 360 |
| 2012 | 264 |
| 2013 | 403 |
| 2014 | 423 |
| 2015 | 619 |
| 2016 | 740 |
| 2017 | 2,296 |
| 2018 | 4,877 |
| 2019 | 5,649 |
| 2020 | 4,766 |
| 2021 | 4,528 |
| 2022 | 4,659 |
| 2023 | 3,922 |
| 2024 | 4,035 |
| 2025 | 3,981 |
| 2026 | 2,657 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
Zeng Q, Xu J, Mu X, et al. · Front Endocrinol (Lausanne) 2023 · Meta-Analysis, Systematic Review
- Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial.
Thammakosol K, Sriphrapradang C · Diabetes Obes Metab 2023 · Randomized Controlled Trial
- Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta-analysis of randomised controlled trials.
Thammakosol K, Vongtangton P, Numthavaj P, et al. · Diabetes Obes Metab 2026 · Systematic Review, Meta-Analysis
- Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Dehghani M, Sadeghi M, Barzkar F, et al. · Front Endocrinol (Lausanne) 2024 · Systematic Review, Network Meta-Analysis
- Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.
Andreadis P, Karagiannis T, Malandris K, et al. · Diabetes Obes Metab 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- [Systematic review with meta-analysis: Subcutaneous insulin glargine coadministration for diabetic ketoacidosis].
Andrade-Castellanos CA, Colunga-Lozano LE · Gac Med Mex 2016 · Meta-Analysis, Systematic Review
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.